Aridis Pharmaceuticals, Inc. announced that it has entered into a Securities Purchase Agreement with individual investors to offer, issue and sell to Investors in a private placement, 4,271,429 shares at an issue price of $0.070 per share for aggregate gross proceeds of approximately $299,000.03 on June 24, 2024. The transaction will include participation from Vu Truong and Eric Patzer. The Common Shares have not been registered under the Securities Act of 1933, as amended (the ?

Securities Act ?), and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.